Mutations and chromosomal rearrangements ofJAK2: not only a myeloid issue

Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a PCM1-JAK2 Fusion Gene

(2013) Elisa Rumi et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

(2013) Kieron Dunleavy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis

(2013) Srdan Verstovsek   POSTGRADUATE MEDICINE

No Evidence for JAK2V617F Mutation in Monoclonal B Cells in 2 Patients with Polycythaemia Vera and Concurrent Monoclonal B Cell Disorder

(2012) C. Stijnis et al.   ACTA HAEMATOLOGICA

Simultaneous and Sequential Concurrent Myeloproliferative and Lymphoproliferative Neoplasms

(2012) Gesa Hauck et al.   ACTA HAEMATOLOGICA

ConcomitantJAK2V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells

(2012) Sabina Swierczek et al.   AMERICAN JOURNAL OF HEMATOLOGY

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia

(2012) E. Lierman et al.   BLOOD

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

(2012) M. Gupta et al.   BLOOD

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

(2012) S. Verstovsek et al.   BLOOD

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection ofJAK2V617F and other relevant mutations

(2012) Anthony J. Bench et al.   BRITISH JOURNAL OF HAEMATOLOGY

New generation small-molecule inhibitors in myeloproliferative neoplasms

(2012) Francesco Passamonti et al.   CURRENT OPINION IN HEMATOLOGY

A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms

(2012) G. Minnucci et al.   HAEMATOLOGICA

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

(2012) A. Chase et al.   HAEMATOLOGICA

Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma

(2012) Daniela Capello et al.   HEMATOLOGICAL ONCOLOGY

Janus Kinase Deregulation in Leukemia and Lymphoma

(2012) Edwin Chen et al.   IMMUNITY

Janus Reveals Another Face: The Biologic Rationale for Targeting Janus Kinase 2 in Lymphoma

(2012) Ann Mullally et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Ubiquitin-dependent regulation of COPII coat size and function

(2012) Lingyan Jin et al.   NATURE

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

(2011) Luca Laurenti et al.   AMERICAN JOURNAL OF HEMATOLOGY

JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma

(2011) K. Van Roosbroeck et al.   BLOOD

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

(2011) F. Passamonti et al.   BLOOD

Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations

(2011) Franziska C Eberle et al.   MODERN PATHOLOGY

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

(2011) Daniela Ungureanu et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis

(2011) Tania Diaz et al.   PLoS One

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma

(2011) E Derenzini et al.   Blood Cancer Journal

Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study

(2010) E. Coyaud et al.   BLOOD

Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates

(2010) Mrinal M. Patnaik et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms

(2010) D. Olcaydu et al.   HAEMATOLOGICA

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients

(2010) E. Rumi et al.   HAEMATOLOGICA

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms

(2010) Wanlong Ma et al.   PLoS One

Absence of the V617F JAK2 Mutation in the Lymphoid Compartment in a Patient with Essential Thrombo- cythemia and B-Chronic Lymphocytic Leukemia and in Two Relatives with Lymphoproliferative Disorders

(2009) Caterina Musolino et al.   ACTA HAEMATOLOGICA

The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

(2009) D Olcaydu et al.   LEUKEMIA

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

(2009) A Tefferi et al.   LEUKEMIA

JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN)

(2009) Srinivas Kodali et al.   LEUKEMIA RESEARCH

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

(2009) Outi Kilpivaara et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Molecular biology of Hodgkin lymphoma

(2009) R. Kuppers   Hematology-American Society of Hematology Education Program

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

NovelSSBP2-JAK2fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia

(2008) Jennifer L. Poitras et al.   GENES CHROMOSOMES & CANCER

JAK2—a new player in acute lymphoblastic leukaemia

(2008) Charles G Mullighan   LANCET

Chronic lymphocytic leukaemia

(2008) G Dighiero et al.   LANCET

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

(2008) Dani Bercovich et al.   LANCET

Aberrant signal transduction pathways in myeloproliferative neoplasms

(2008) J Kota et al.   LEUKEMIA

Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia

(2008) K Nebral et al.   LEUKEMIA

Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell?

(2008) Piotr Tabaczewski et al.   LEUKEMIA RESEARCH

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma

(2007) L. T. Lam et al.   BLOOD